Location Directory

Clinical trials in Washington D.C., District of Columbia

This page shows live ClinicalTrials.gov search results for Washington D.C., District of Columbia, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:55 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

182

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Breast Cancer
Interventions: systemic chemotherapy, axillary lymph node dissection, neoadjuvant therapy, sentinel lymph node biopsy, therapeutic conventional surgery, ultrasound imaging; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 324
States / cities: Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 232 more

Conditions: Non-Cystic Fibrosis Bronchiectasis
Interventions: Brensocatib 10 mg, Brensocatib 25 mg, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 36
States / cities: Birmingham, Alabama • Peoria, Arizona • Newport Beach, California + 30 more

Conditions: Leukemia
Interventions: mercaptopurine, methotrexate, tretinoin; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 210
States / cities: Scottsdale, Arizona • Roseville, California • Sacramento, California + 135 more

Conditions: Lymphoma, Nonneoplastic Condition
Interventions: bleomycin sulfate, filgrastim, ABVD regimen, BEACOPP regimen, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 60 Years
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 423
States / cities: Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 290 more

Conditions: Breast Cancer
Interventions: cyclophosphamide, adriamycin, epirubicin, fluorouracil; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 2,722 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 586
States / cities: Huntsville, Alabama • Anchorage, Alaska • Glendale, Arizona + 396 more

Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: Pacritinib, Best Available Therapy; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 50
States / cities: Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more

Conditions: HIV Infections
Interventions: Recombinant interleukin-2 (rIL-2); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 78
States / cities: Los Angeles, California • Mill Valley, California • Oakland, California + 33 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Nevirapine, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 58
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 39 more

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 95
States / cities: Birmingham, Alabama • Los Angeles, California • Pasadena, California + 50 more

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Months to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 53
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 32 more

Conditions: Bacterial Infections, Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Azithromycin, Atovaquone, Sulfamethoxazole-Trimethoprim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 18 Months
Enrollment: 690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 46 more

Conditions: HIV Infections, Tuberculosis
Interventions: Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 75
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 39 more

Clinical trials in Washington D.C., District of Columbia

Filter and sort this location

Live official records

Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)

Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens

A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children

Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection